secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001140361-24-043915
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.03, 2.01, 2.02, 3.02, 3.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire completes merger with Opus Genetics; renamed Opus Genetics with $37M pro forma cash
--------------------------------------------------------------------------------

- Merger closed Oct 22; Ocuphire issued ~5.24M common shares and 14,145 Series A Preferred (convertible into ~14.1M common) to Opus securityholders.
- Pro forma cash ~$37M as of Sep 30, 2024; cash runway expected into 2026.
- Name changed to Opus Genetics, Inc. effective Oct 23; ticker begins trading as 'IRD' on Oct 24, 2024.
- Dr. Benjamin Yerxa appointed President; base salary $425,000, 35% target bonus, 332,800 RSUs; Board expanded to 9.
- 180-day lock-up agreements on shares held by certain stockholders and all directors/officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124043915/0001140361-24-043915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124043915/ef20037500_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-043915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer